Sanofi (SAN) ESG Investor Roadshow conference summary
Event summary combining transcript, slides, and related documents.
ESG Investor Roadshow conference summary
3 Feb, 2026Opening and strategic context
Event focused on ESG strategy, highlighting integration of sustainability into business growth and value creation for society, patients, and the environment.
Agenda included deep dives on access to healthcare, environmental impact, healthcare system resilience, and inclusion.
Emphasis on business representatives sharing sustainability execution and alignment with the Play to Win strategy.
Sustainability strategy and AIR program
Refreshed AIR strategy focuses on Access, Impact, and Resilience, validated by executive committee and board, and fully integrated into business planning.
Transitioning from flagship commitments to a holistic, integrated approach involving all business units and functions.
Sustainability fundamentals are being embedded across the value chain to drive responsible business practices.
Ongoing evaluation and adjustment of goals, metrics, and targets in response to evolving standards and risks.
Access to healthcare initiatives
Programs target vulnerable populations in international markets and LMICs, focusing on respiratory and diabetes care, school-based education, and mobile health units.
Over 931,000 patients reached with NCD treatments in 33 countries; goal to reach 1.5 million by 2026.
Global Health Unit operates as a not-for-profit, reaching nearly 1 million patients in 40 countries, with investments in healthcare startups impacting 10 million patients.
Business models range from full-value to inclusive, with partnerships to elevate care standards.
Latest events from Sanofi
- Pipeline progress, margin expansion, and strategic investments drive future growth.SAN
Morgan Stanley 23rd Annual Global Healthcare Conference9 Jul 2026 - 2025 delivered double-digit sales and EPS growth, led by innovation and strong capital returns.SAN
Q4 20259 Jul 2026 - Double-digit growth, strong pipeline, and €5bn buyback set up robust 2025 outlook.SAN
Q4 20249 Jul 2026 - Q3 sales up 16% CER to €13.4B, with upgraded EPS guidance and strong pipeline momentum.SAN
Q3 20249 Jul 2026 - Tolebrutinib delayed disability progression in MS by up to 31% with manageable liver risk.SAN
Status Update8 Jul 2026 - Q1 2025 delivered 9.7% sales growth, 15.7% EPS rise, and confirmed guidance for the year.SAN
Q1 20258 Jul 2026 - Multiple late-stage trials, global RSV expansion, and digital adaptation drive near-term growth.SAN
Jefferies Global Healthcare Conference 20264 Jun 2026 - Q1 2026 saw 13.6% sales and 14% EPS growth, driven by Dupixent and new launches.SAN
Q1 202626 Apr 2026 - Strong 2024 growth, innovation, and all resolutions passed with high approval.SAN
AGM 20253 Feb 2026